PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Anticholinergic Exposure Reaches 74% in Community-Dwelling Elders, Scales Disagree

anticholinergic burdenbenzodiazepinesolder adultsdeprescribingACBARSADSDBIABCpolypharmacygeriatric pharmacyBeers CriteriaSTOPP/STARTcross-sectional studymedication safety Geriatrics / Geriatric Pharmacy

Background Information

Anticholinergic burden is prevalent but tricky to measure in elders.

Anticholinergic burden is a key concern for medication management in older adults, impacting cognitive and physical health. 74.2% of older adults take medications with anticholinergic properties, yet agreement between assessment scales is only moderate to weak. Clinicians should use multiple tools to accurately identify and minimize anticholinergic exposure, considering safer alternatives to reduce risk. High anticholinergic use in older adults necessitates careful drug assessment to mitigate risks.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Rodríguez-Salas FB, Merchán-Cruz MA, Ocaña-Riola R, Díez-de-Baldeón-Chicón PM, Lara JP, Blanco-Reina E

Citation: Rodríguez-Salas FB, Merchán-Cruz MA, Ocaña-Riola R, et al. Anticholinergic burden in community-dwelling older adults: prevalence, associated factors, and agreement between measurement scales. Frontiers in pharmacology. 2026;17:1886899. doi:10.3389/fphar.2026.1886899

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.